<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02469623</url>
  </required_header>
  <id_info>
    <org_study_id>CL-SVT-005</org_study_id>
    <secondary_id>CL-SVT-002</secondary_id>
    <secondary_id>CL-SVT-001</secondary_id>
    <secondary_id>CL-SVT-004</secondary_id>
    <secondary_id>CL-SVT-006</secondary_id>
    <secondary_id>CL-SVT-008</secondary_id>
    <nct_id>NCT02469623</nct_id>
    <nct_alias>NCT01875614</nct_alias>
    <nct_alias>NCT01914549</nct_alias>
    <nct_alias>NCT01921660</nct_alias>
    <nct_alias>NCT02469636</nct_alias>
    <nct_alias>NCT02469649</nct_alias>
  </id_info>
  <brief_title>Dipole Density Mapping in Supraventricular Tachycardia</brief_title>
  <acronym>DDRAMATIC-SVT</acronym>
  <official_title>Dipole Density Right (and Left) Atrial Mapping and Assessment of Therapy In Complex Supraventricular Tachycardia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acutus Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acutus Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Use of dipole density mapping to identify activation in complex supraventricular
      tachycardias.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The research study was conducted in multiple countries throughout the EU and Canada. The
      protocol and their corresponding NCT numbers are as follows:

      NCT01914549 (Protocol CL-SVT-001, Site Belgium, Bruges Dr. Duytschaever = PI) NCT01875614
      (Protocol CL-SVT-002, Sites in the UK, Drs. Grace, Hall, &amp; Schilling = PIs) NCT03368781
      (Protocol CL-SVT-004, Site Hamburg, Germany Prof. Willems = PI) NCT02469623 (Protocol
      CL-SVT-005, Site Prague, Czech Republic Prof. Neuzil = PI) NCT02469636 (Protocol CL-SVT-006,
      Site Santiago, Chile Dr. Bittner = PI) NCT02469649 (Protocol CL-SVT-008, Site Ontario, Canada
      Dr. Verma = PI)

      All of the above records were combined into one as all protocols were essentially identical
      and one study report was written that encompasses the data/results for all protocols.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2014</start_date>
  <completion_date type="Actual">May 22, 2017</completion_date>
  <primary_completion_date type="Actual">May 22, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events</measure>
    <time_frame>7 days</time_frame>
    <description>Sites reported all adverse events throughout the study follow-up period regardless of their relationship to the device or procedure. Each event was classified and adjudicated by the site-specific investigator. The data were further analyzed by the Sponsor medical reviewer, providing a consistent determination of relationship to device, procedure and the subjects' underlying disease of the atrial arrhythmia condition.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Number of Patients for Which Activation Maps Can be Created</measure>
    <time_frame>1 day</time_frame>
    <description>The primary performance endpoint was the number of subjects with successful construction of pre- and post-ablation procedure activation maps.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Supraventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Dipole Density Mapping</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dipole Density Mapping with AcQMap followed by ablation</intervention_name>
    <arm_group_label>Dipole Density Mapping</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Be aged 18-75 years

          2. Be scheduled for ablation of an SVT due to the arrhythmia being recurrent, poorly
             tolerated, and /or unable to be controlled with antiarrhythmic drugs.

          3. Be able and willing to give informed consent

        Exclusion Criteria

          1. Have any of the following:

               -  implanted prosthetic, artificial, or repaired cardiac valves in the chamber being
                  mapped

               -  permanent pacemaker or ICD leads in the chamber being mapped

               -  hypercoagulopathy or an inability to tolerate anticoagulation during the
                  procedure

               -  Stents in the area of the pulmonary veins (Study CL-SVT-004 ONLY)

          2. MI within the prior two (2) months

          3. Cardiac surgery within the prior three (3) months

          4. Intracardiac thrombus

          5. Clinically significant tricuspid and/or mitral valve regurgitation or stenosis

          6. Cerebral ischemic event (including TIA) in the prior six (6) months

          7. Pregnant or nursing

          8. Currently enrolled in another clinical investigation

          9. Have a contraindication for transfemoral venous access (Study CL-SVT-004 ONLY)

         10. Have a contraindication for transseptal left atrial access (for patients with left
             atrial arrhythmias) (Study CL-SVT-004 ONLY)

         11. Life expectancy of less than one (1) year (Study CL-SVT-004 ONLY)

         12. Any health condition that, in the Investigator's opinion, would not allow the
             application of the investigational device (Study CL-AF-004 ONLY)

        NOTE: The additional exclusion criteria for CL-SVT-004 were not expected to alter or bias
        the patient selection for study enrollment. While these criteria would have been assumed by
        other investigators as a standard of care for safe enrollment in a clinical study, the
        German EC approval required the additional statements.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Neuzil, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nemocnice Na Homolce</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint-Jan AV Cardiologie</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Center</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <zip>Región Metropolitana</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>150 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elektrophysiologie Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>D - 20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB23</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Heart and Chest Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 3PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barts Health NHS Trust</name>
      <address>
        <city>Whitechapel</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 8, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2015</study_first_posted>
  <results_first_submitted>April 16, 2019</results_first_submitted>
  <results_first_submitted_qc>August 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2019</results_first_posted>
  <last_update_submitted>August 15, 2019</last_update_submitted>
  <last_update_submitted_qc>August 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/23/NCT02469623/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Treated Subjects</title>
          <description>Subjects scheduled for an ablation of a supraventricular tachycardia due to the arrhythmia being recurrent using the AcQMap High Resolution Imaging and Mapping System (AcQMap System) in gathering data to create right and/or left atrial dipole density activation maps in subjects with supraventricular tachycardias (SVTs).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not consented for long-term follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dipole Density Mapping</title>
          <description>Subjects scheduled for an ablation of a supraventricular tachycardia due to the arrhythmia being recurrent using the AcQMap High Resolution Imaging and Mapping System (AcQMap System) in gathering data to create right and/or left atrial dipole density activation maps in subjects with supraventricular tachycardias (SVTs).
Follow-up is 7-10 days for non-AF patients (except in Germany where all subjects were followed for 1 year) and 1 year for AF patients following the procedure for each patient.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="85"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chile</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events</title>
        <description>Sites reported all adverse events throughout the study follow-up period regardless of their relationship to the device or procedure. Each event was classified and adjudicated by the site-specific investigator. The data were further analyzed by the Sponsor medical reviewer, providing a consistent determination of relationship to device, procedure and the subjects' underlying disease of the atrial arrhythmia condition.</description>
        <time_frame>7 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treated Subjects</title>
            <description>Subjects scheduled for an ablation of a supraventricular tachycardia due to the arrhythmia being recurrent using the AcQMap High Resolution Imaging and Mapping System (AcQMap System) in gathering data to create right and/or left atrial dipole density activation maps in subjects with supraventricular tachycardias (SVTs).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Freedom From Device-and Procedure-related Adverse Events and Serious Adverse Events</title>
          <description>Sites reported all adverse events throughout the study follow-up period regardless of their relationship to the device or procedure. Each event was classified and adjudicated by the site-specific investigator. The data were further analyzed by the Sponsor medical reviewer, providing a consistent determination of relationship to device, procedure and the subjects' underlying disease of the atrial arrhythmia condition.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AF Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-AF Subjects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom a device related SAE @ 7dys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from a procedure-related SAE @ 7-dys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from an related AcQGuide SAE @ 7-dys</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from a device related AE @ 7-days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from a procedure-related AE @ 7-days post</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from an AcQGuide Sheath related AE @ 7-day</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Number of Patients for Which Activation Maps Can be Created</title>
        <description>The primary performance endpoint was the number of subjects with successful construction of pre- and post-ablation procedure activation maps.</description>
        <time_frame>1 day</time_frame>
        <population>The study population consists of men and women between the ages of 18 – 75 years of age scheduled for an endocardial ablation for a supraventricular tachycardia (SVT)</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects Scheduled for Ablation of an SVT</title>
            <description>Subjects scheduled for ablation of a supraventricular tachycardia (SVT) due to the arrhythmia being recurrent, poorly tolerated and/or unable to be controlled with antiarrhythmic drug therapy</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Patients for Which Activation Maps Can be Created</title>
          <description>The primary performance endpoint was the number of subjects with successful construction of pre- and post-ablation procedure activation maps.</description>
          <population>The study population consists of men and women between the ages of 18 – 75 years of age scheduled for an endocardial ablation for a supraventricular tachycardia (SVT)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-procedure activation maps</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-procedure activation maps</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Follow-up is 7-10 days for non-AF subjects (except in Germany where all subjects were followed for 1 year) and 1 year for AF patients following the procedure for each subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Treated Subjects</title>
          <description>Subjects scheduled for an ablation of a supraventricular tachycardia due to the arrhythmia being recurrent using the AcQMap High Resolution Imaging and Mapping System (AcQMap System) in gathering data to create right and/or left atrial dipole density activation maps in subjects with supraventricular tachycardias (SVTs).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of Breath</sub_title>
                <description>Progressive shortness of breath secondary to noted heart failure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <description>On 09-MAY-2016 the pacemaker was implanted due to poly-arrhythmia symptoms and due to bradycardia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <description>Cardiac Arrest</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>Patient went into fast AF rate 160, this lasted 3-4 hours. The event returned, and the patient was treated at another hospital and pacemaker was inserted on the 3rd August 2016</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <description>Patient presented to emergency room in flutter. He was given 500mcg x 2 Digoxin and this terminated the flutter into AF. He was discharged the following day.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal Thyroid Function</sub_title>
                <description>Post ablation admitted with abnormal thyroid function labs. Amiodarone stopped</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chest Infection</sub_title>
                <description>Patient thought to have developed chest infection. Antibiotics started and discharged 18 May 2016</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Carcinomamammae sin</sub_title>
                <description>Pt undergone the surgical resection on 18/NOV/2016 and was discharged from hospital on 22-Nov-2016. Recent check confirmed that marker tumors are normal.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Brain Tumor</sub_title>
                <description>Patient was experiencing memory loss. The patient was assessed, CT head performed, followed by an MRI of the head. Diagnosis of glioblastoma multiforme</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal Insufficiency</sub_title>
                <description>Patient was hospitalized due to acute renal insufficiency with anuria, hyperkalemia and signs of systemic infection of unknown etiology.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Access site Injury</sub_title>
                <description>Hematoma right groin. Resolved without treatment. Remained in hospital for observation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Ablation re-do requiring hospitalization</sub_title>
                <description>Atrial Fibrillation ablation Re-do</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Valve Dysfunction</sub_title>
                <description>Worsening of mitral valve regurgitation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoid Bleeding</sub_title>
                <description>Hemorrhage from Hemorrhoid</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal ECG</sub_title>
                <description>Right bundle branch block</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <description>AF recurrence with dyspnea and fatigue</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <description>Patient described retrosternal chest pain. Echocardiogram shows no pericardial effusion. Mild analgesics prescribed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Dizziness and Syncope</sub_title>
                <description>Then patient complains of feeling frequently dizzy and as though he will pass out. ECG today shows sinus rhythm at 49bpm. No treatment prescribed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Exertional Dyspnea</sub_title>
                <description>Dyspnea on Exertion. Sotolol discontinued</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <description>Hypertension</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <description>Patient developed pericarditis 48 hr. post procedure, resolved with NSAIDS.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Pleuritic Chest pain</sub_title>
                <description>Patient suffered pleuritic chest pain post procedure. Negative work up and mild analgesics prescribed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <description>By 7 days FU, patient mentioned shortness of breath. Negative chest work up. Abnormal labs for thyroid function noted. AAD medication changed</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Symptomatic Palpitations</sub_title>
                <description>Palpitations and extra systolic beats</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Syncopal episodes</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Tonsilitis</sub_title>
                <description>Tonsilitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Rivaroxaban stopped - Apixaban started due to Diarrhea</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Lower Extremity Swelling</sub_title>
                <description>Swelling of Lower Extremities</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Stumble/Fall</sub_title>
                <description>Stumble fall on the street</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Swollen Legs</sub_title>
                <description>Swollen Legs. Amlodipine discontinued</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <description>Patient feels dizzy and had a hematoma in the right eye. 24 hours post-procedure diagnosed with recurrent AF</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abnormal lab value/infection</sub_title>
                <description>Leukocytosis as noted by changes in lab values. Controlled by primary care Doctor.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <description>Infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arm Fracture</sub_title>
                <description>Broken neck of the Humerus</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Access site injury</sub_title>
                <description>groin hematoma</description>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Air embolism/ST change</sub_title>
                <description>An apparent air embolism from the AcQGuide Sheath caused a brief (1-2 min) change in ST segment that resolved without treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="85"/>
              </event>
              <event>
                <sub_title>Groin Hematoma</sub_title>
                <description>Groin Hematoma</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="85"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steve McQuillan, Sr. Vice President Regulatory, Clinical, &amp; Quality Assurance</name_or_title>
      <organization>Acutus Medical, Inc.</organization>
      <phone>442232608-</phone>
      <email>steven.mcquillan@acutus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

